Disease Overview
Epilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological Disorders and Stroke as causing "strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness." There are many possible causes of epilepsy including cerebrovascular disease, brain injury, abnormal brain development, central nervous system infection, tumors, and genetic factors.
Market Snapshot
Epilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological Disorders and Stroke as causing "strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness." There are many possible causes of epilepsy including cerebrovascular disease, brain injury, abnormal brain development, central nervous system infection, tumors, and genetic factors.
Market Snapshot
- Label expansions will drive uptake of newer brands, sustaining the epilepsy market by countering widespread genericization.
- Levetiracetam, valproate formulations, lamotrigine, and carbamazepine constitute the mainstay of epilepsy treatment.
- Although approximately 70% of epilepsy patients respond to treatment, the number of prevalent cases of active epilepsy remains high.
- UCB will continue to dominate the epilepsy market with key drugs Keppra and Vimpat.
- With positive Phase III data in LGS, Epidiolex is proving to be the therapy of choice for refractory childhood epilepsy.
Table of Contents
FORECAST: EPILEPSY (Published on 11 July 2017)
- Overview
- Executive Summary
- Market Overview And Trends
- Market Definition And Methodology
- Aptiom/Zebinix (Eslicarbazepine)
- Banzel/Inovelon (Rufinamide)
- Briviact (Brivaracetam)
- Epidiolex (Cannabidiol)
- Fycompa (Perampanel)
- Keppra/Keppra Xr (Levetiracetam)
- Lamictal/Lamictal Xr (Lamotrigine)
- Lyrica (Pregabalin)
- Onfi (Clobazam)
- Vimpat (Lacosamide)
- Primary Research Methodology
TREATMENT: EPILEPSY (Published on 31 May 2017)
- Overview
- Executive Summary
- Primary Research Methodology
- Disease Definition And Diagnosis
- Patient Segmentation
- Current Treatment Options
- Treatment Dynamics
- Unmet Needs In Epilepsy
EPIDEMIOLOGY: EPILEPSY (Published on 26 July 2019)
- Overview
- Disease Background
- Methodology
- Forecast
- Bibliography
- Appendix: Additional Sources
MARKETED DRUGS: EPILEPSY (Published on 23 May 2017)
- Overview
- Executive Summary
- Product Overview
- Product Profile: Aptiom
- Product Profile: Banzel
- Product Profile: Briviact
- Product Profile: Fycompa
- Product Profile: Keppra And Keppra Xr
- Product Profile: Lamictal And Lamictal Xr
- Product Profile: Lyrica
- Product Profile: Onfi
- Product Profile: Vimpat
PIPELINE: EPILEPSY (Published on 02 October 2017)
- Overview
- Executive Summary
- Clinical Pipeline Overview
- Latest Analyst Opinion
- Additional Pharma Intelligence Pipeline Resources
- Product Profile (Late Stage): Epidiolex
- Product Profile (Late Stage): Ganaxolone
LIST OF FIGURES
Figure 1: Epilepsy market sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: Growth dynamics of the epilepsy market across the US, Japan, and five major EU markets, by country, 2016–25
Figure 3: Epilepsy market sales across the US, Japan, and five major EU markets, by epilepsy subtype, 2016–25
Figure 4: Epilepsy market sales across the US, Japan, and five major EU markets, by drug type, 2016–25
Figure 5: Sales of selected competing POS brands across the US, Japan, and five major EU markets, 2016–25
Figure 6: Sales of selected competing LGS brands across the US, Japan, and five major EU markets, 2016–25
Figure 7: Methodology flow for The author's epilepsy patient-based forecast
Figure 8: Price sources and calculations, by country
Figure 9: Aptiom/Zebinix sales for epilepsy across the US and five major EU markets, by country, 2016–25
Figure 10: Banzel/Inovelon sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 11: Briviact sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Epidiolex sales for epilepsy across the US and five major EU markets, by country, 2016–25
Figure 13: Fycompa sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Keppra/Keppra XR sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Lamictal/Lamictal XR sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Lyrica sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 17: Onfi sales for epilepsy in the US, 2016–25
Figure 18: Vimpat sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 19: Classification of epilepsy seizures
Figure 20: Diagnosis rates for epilepsy in the US, Japan, and five major EU markets, by country
Figure 21: Segmentation of epilepsy patients by seizure subtype in the US, Japan, and five major EU markets, by country
Figure 22: Segmentation of epilepsy patients by treatment response in the US, Japan, and five major EU markets, by country
Figure 23: Drug treatment rate for epilepsy in the US, Japan, and five major EU markets, by country
Figure 24: Levels of efficacy and effectiveness evidence supporting use of AEDs in epilepsy subpopulations*
Figure 25: First- and second-line therapies recommended for epilepsy subpopulations in the UK
Figure 26: Top four overall drug treatments across the US, Japan, and five major EU markets, by epilepsy subtype
Figure 27: Average ranking of drugs across the US, Japan, and five major EU markets for all epilepsy subtypes
Figure 28: Top five drug treatments for treatment-responsive POS in the US, Japan, and five major EU markets, by country
Figure 29: Top five drug treatments for treatment-refractory POS in the US, Japan, and five major EU markets, by country
Figure 30: Top five drug treatments for treatment-responsive generalized seizures in the US, Japan, and five major EU markets, by country
Figure 31: Top five drug treatments for treatment-refractory generalized seizures in the US, Japan, and five major EU markets, by country
Figure 32: Compliance rates of epilepsy patients in the US, Japan, and five major EU markets, by country, seizure type, and responsiveness to treatment
Figure 33: Key unmet needs for epilepsy, 2016
Figure 34: Trends in diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, by country, 2018–38
Figure 35: Aptiom for epilepsy – SWOT analysis
Figure 36: The author's drug assessment summary for Aptiom in epilepsy
Figure 37: The author's drug assessment summary for Aptiom in epilepsy
Figure 38: Banzel for epilepsy – SWOT analysis
Figure 39: The author's drug assessment summary for Banzel in epilepsy
Figure 40: The author's drug assessment summary for Banzel in epilepsy
Figure 41: Briviact for epilepsy – SWOT analysis
Figure 42: The author's drug assessment summary for Briviact in epilepsy
Figure 43: The author's drug assessment summary for Briviact in epilepsy
Figure 44: Fycompa for epilepsy – SWOT analysis
Figure 45: The author's drug assessment summary for Fycompa in epilepsy
Figure 46: The author's drug assessment summary for Fycompa in epilepsy
Figure 47: Keppra and Keppra XR for epilepsy – SWOT analysis
Figure 48: The author's drug assessment summary for Keppra in epilepsy
Figure 49: The author's drug assessment summary for Keppra in epilepsy
Figure 50: Lamictal/Lamictal XR for epilepsy – SWOT analysis
Figure 51: The author's drug assessment summary for Lamictal in epilepsy
Figure 52: The author's drug assessment summary for Lamictal in epilepsy
Figure 53: Lyrica for epilepsy – SWOT analysis
Figure 54: The author's drug assessment summary for Lyrica in epilepsy
Figure 55: The author's drug assessment summary for Lyrica in epilepsy
Figure 56: Onfi for epilepsy – SWOT analysis
Figure 57: The author's drug assessment summary for Onfi in epilepsy
Figure 58: The author's drug assessment summary for Onfi in epilepsy
Figure 59: Vimpat for epilepsy – SWOT analysis
Figure 60: The author's drug assessment summary for Vimpat in epilepsy
Figure 61: The author's drug assessment summary for Vimpat in epilepsy
Figure 62: Epidiolex for epilepsy – SWOT analysis
Figure 63: The author's drug assessment summary for Epidiolex in epilepsy
Figure 64: The author's drug assessment summary for Epidiolex in epilepsy
Figure 65: Ganaxolone for epilepsy – SWOT analysis
Figure 66: The author's drug assessment summary for ganaxolone in epilepsy
Figure 67: The author's drug assessment summary for ganaxolone in epilepsy
Figure 2: Growth dynamics of the epilepsy market across the US, Japan, and five major EU markets, by country, 2016–25
Figure 3: Epilepsy market sales across the US, Japan, and five major EU markets, by epilepsy subtype, 2016–25
Figure 4: Epilepsy market sales across the US, Japan, and five major EU markets, by drug type, 2016–25
Figure 5: Sales of selected competing POS brands across the US, Japan, and five major EU markets, 2016–25
Figure 6: Sales of selected competing LGS brands across the US, Japan, and five major EU markets, 2016–25
Figure 7: Methodology flow for The author's epilepsy patient-based forecast
Figure 8: Price sources and calculations, by country
Figure 9: Aptiom/Zebinix sales for epilepsy across the US and five major EU markets, by country, 2016–25
Figure 10: Banzel/Inovelon sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 11: Briviact sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Epidiolex sales for epilepsy across the US and five major EU markets, by country, 2016–25
Figure 13: Fycompa sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Keppra/Keppra XR sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Lamictal/Lamictal XR sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Lyrica sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 17: Onfi sales for epilepsy in the US, 2016–25
Figure 18: Vimpat sales for epilepsy across the US, Japan, and five major EU markets, by country, 2016–25
Figure 19: Classification of epilepsy seizures
Figure 20: Diagnosis rates for epilepsy in the US, Japan, and five major EU markets, by country
Figure 21: Segmentation of epilepsy patients by seizure subtype in the US, Japan, and five major EU markets, by country
Figure 22: Segmentation of epilepsy patients by treatment response in the US, Japan, and five major EU markets, by country
Figure 23: Drug treatment rate for epilepsy in the US, Japan, and five major EU markets, by country
Figure 24: Levels of efficacy and effectiveness evidence supporting use of AEDs in epilepsy subpopulations*
Figure 25: First- and second-line therapies recommended for epilepsy subpopulations in the UK
Figure 26: Top four overall drug treatments across the US, Japan, and five major EU markets, by epilepsy subtype
Figure 27: Average ranking of drugs across the US, Japan, and five major EU markets for all epilepsy subtypes
Figure 28: Top five drug treatments for treatment-responsive POS in the US, Japan, and five major EU markets, by country
Figure 29: Top five drug treatments for treatment-refractory POS in the US, Japan, and five major EU markets, by country
Figure 30: Top five drug treatments for treatment-responsive generalized seizures in the US, Japan, and five major EU markets, by country
Figure 31: Top five drug treatments for treatment-refractory generalized seizures in the US, Japan, and five major EU markets, by country
Figure 32: Compliance rates of epilepsy patients in the US, Japan, and five major EU markets, by country, seizure type, and responsiveness to treatment
Figure 33: Key unmet needs for epilepsy, 2016
Figure 34: Trends in diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, by country, 2018–38
Figure 35: Aptiom for epilepsy – SWOT analysis
Figure 36: The author's drug assessment summary for Aptiom in epilepsy
Figure 37: The author's drug assessment summary for Aptiom in epilepsy
Figure 38: Banzel for epilepsy – SWOT analysis
Figure 39: The author's drug assessment summary for Banzel in epilepsy
Figure 40: The author's drug assessment summary for Banzel in epilepsy
Figure 41: Briviact for epilepsy – SWOT analysis
Figure 42: The author's drug assessment summary for Briviact in epilepsy
Figure 43: The author's drug assessment summary for Briviact in epilepsy
Figure 44: Fycompa for epilepsy – SWOT analysis
Figure 45: The author's drug assessment summary for Fycompa in epilepsy
Figure 46: The author's drug assessment summary for Fycompa in epilepsy
Figure 47: Keppra and Keppra XR for epilepsy – SWOT analysis
Figure 48: The author's drug assessment summary for Keppra in epilepsy
Figure 49: The author's drug assessment summary for Keppra in epilepsy
Figure 50: Lamictal/Lamictal XR for epilepsy – SWOT analysis
Figure 51: The author's drug assessment summary for Lamictal in epilepsy
Figure 52: The author's drug assessment summary for Lamictal in epilepsy
Figure 53: Lyrica for epilepsy – SWOT analysis
Figure 54: The author's drug assessment summary for Lyrica in epilepsy
Figure 55: The author's drug assessment summary for Lyrica in epilepsy
Figure 56: Onfi for epilepsy – SWOT analysis
Figure 57: The author's drug assessment summary for Onfi in epilepsy
Figure 58: The author's drug assessment summary for Onfi in epilepsy
Figure 59: Vimpat for epilepsy – SWOT analysis
Figure 60: The author's drug assessment summary for Vimpat in epilepsy
Figure 61: The author's drug assessment summary for Vimpat in epilepsy
Figure 62: Epidiolex for epilepsy – SWOT analysis
Figure 63: The author's drug assessment summary for Epidiolex in epilepsy
Figure 64: The author's drug assessment summary for Epidiolex in epilepsy
Figure 65: Ganaxolone for epilepsy – SWOT analysis
Figure 66: The author's drug assessment summary for ganaxolone in epilepsy
Figure 67: The author's drug assessment summary for ganaxolone in epilepsy
LIST OF TABLES
Table 1: Epilepsy market sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Epilepsy market sales across the US, Japan, and five major EU markets, by epilepsy subtype ($m), 2016–25
Table 3: Epilepsy market sales across the US, Japan, and five major EU markets, by drug type ($m), 2016–25
Table 4: Sales of selected competing POS brands across the US, Japan, and five major EU markets ($m), 2016–25
Table 5: Sales of selected competing LGS brands across the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Exchange rates used for calculating prices
Table 7: Estimated patent expiry/loss of exclusivity dates for key marketed brands in epilepsy, by country, 2016–25
Table 8: Estimated launch and approval dates for key products in epilepsy, by country, 2016–25
Table 9: Aptiom/Zebinix sales for epilepsy across the US and five major EU markets, by country ($m), 2016–25
Table 10: Banzel/Inovelon sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Briviact sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 12: Epidiolex sales for epilepsy across the US and five major EU markets, by country ($m), 2016–25
Table 13: Fycompa sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: Keppra/Keppra XR sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 15: Lamictal/Lamictal XR sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Lyrica sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 17: Onfi sales for epilepsy in the US ($m), 2016–25
Table 18: Vimpat sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 19: Neurologists surveyed for the epilepsy primary research study, 2016
Table 20: Neurologists surveyed for the epilepsy primary research study, 2016
Table 21: Diagnosis rates for epilepsy in the US, Japan, and five major EU markets, by country (%)
Table 22: Segmentation of epilepsy patients by seizure subtype in the US, Japan, and five major EU markets, by country (%)
Table 23: Segmentation of epilepsy patients by treatment response in the US, Japan, and five major EU markets, by country (%)
Table 24: Drug treatment rate for epilepsy in the US, Japan, and five major EU markets, by country (%)
Table 25: Leading therapies for epilepsy
Table 26: Leading drug treatments according to patient share across the US, Japan, and five major EU markets, by epilepsy subtype (%)
Table 27: Drug treatments for treatment-responsive POS in the US, Japan, and five major EU markets, by country (%)
Table 28: Drug treatments for treatment-refractory partial-onset seizures in the US, Japan, and five major EU markets, by country (%)
Table 29: Drug treatments for treatment-responsive generalized seizures in the US, Japan, and five major EU markets, by country (%)
Table 30: Drug treatments for treatment-refractory generalized seizures in the US, Japan, and five major EU markets, by country (%)
Table 31: Compliance rates of epilepsy patients in the US, Japan, and five major EU markets, by country, seizure type, and responsiveness to treatment (%)
Table 32: Sources used for the epidemiological analysis of epilepsy in the US, Japan, and five major EU markets, by country
Table 33: Diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, by country, 2018–38
Table 34: Key marketed drugs for epilepsy
Table 35: Aptiom epilepsy indication approvals
Table 36: Aptiom drug profile
Table 37: Aptiom pivotal trial data in epilepsy
Table 38: Ongoing late-phase trials
Table 39: Banzel drug profile
Table 40: Banzel pivotal trial data in epilepsy
Table 41: Safety profile for Banzel in epilepsy
Table 42: Briviact drug profile
Table 43: Briviact pivotal trial data in epilepsy
Table 44: Fycompa epilepsy indication approvals
Table 45: Fycompa drug profile
Table 46: Fycompa pivotal trial data in epilepsy
Table 47: Ongoing late-phase trials
Table 48: Keppra/Keppra XR epilepsy indication approvals
Table 49: Keppra and Keppra XR drug profile
Table 50: Keppra pivotal trial data in epilepsy
Table 51: Safety profile for Keppra in epilepsy
Table 52: Keppra XR pivotal trial data in epilepsy
Table 53: Safety profile for Keppra XR in epilepsy
Table 54: Lamictal/Lamictal XR epilepsy indication approvals
Table 55: Lamictal and Lamictal XR drug profile
Table 56: Lamictal pivotal trial data in epilepsy
Table 57: Safety profile for Lamictal in epilepsy
Table 58: Lamictal XR pivotal trial data in epilepsy
Table 59: Safety profile for Lamictal XR in epilepsy
Table 60: Lyrica drug profile
Table 61: Lyrica pivotal trial data in epilepsy
Table 62: Safety profile for Lyrica in epilepsy
Table 63: Pfizer late-phase trial data in partial-onset epilepsy
Table 64: Lyrica ongoing late-phase trials for pediatric and adult epilepsy indications
Table 65: Onfi drug profile
Table 66: Onfi pivotal trial data in epilepsy
Table 67: Safety profile for Onfi in epilepsy
Table 68: Vimpat epilepsy indication approvals
Table 69: Vimpat drug profile
Table 70: Vimpat pivotal trial data in epilepsy
Table 71: Safety profile for Vimpat in epilepsy
Table 72: Vimpat late-phase trial data in epilepsy
Table 73: Vimpat ongoing late-phase clinical trials as monotherapy in epilepsy
Table 74: Pipeline products in development for epilepsy
Table 75: ZX008 Phase III trial in Dravet syndrome
Table 76: Epidiolex drug profile
Table 77: Epidiolex Phase II/III data in epilepsy
Table 78: Epidiolex physician-led expanded access program data
Table 79: Epidiolex Phase III trials in Dravet syndrome, tuberous sclerosis complex, and infantile spasms
Table 80: Ganaxolone drug profile
Table 81: Ganaxolone Phase II/III data in epilepsy
Table 2: Epilepsy market sales across the US, Japan, and five major EU markets, by epilepsy subtype ($m), 2016–25
Table 3: Epilepsy market sales across the US, Japan, and five major EU markets, by drug type ($m), 2016–25
Table 4: Sales of selected competing POS brands across the US, Japan, and five major EU markets ($m), 2016–25
Table 5: Sales of selected competing LGS brands across the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Exchange rates used for calculating prices
Table 7: Estimated patent expiry/loss of exclusivity dates for key marketed brands in epilepsy, by country, 2016–25
Table 8: Estimated launch and approval dates for key products in epilepsy, by country, 2016–25
Table 9: Aptiom/Zebinix sales for epilepsy across the US and five major EU markets, by country ($m), 2016–25
Table 10: Banzel/Inovelon sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Briviact sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 12: Epidiolex sales for epilepsy across the US and five major EU markets, by country ($m), 2016–25
Table 13: Fycompa sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: Keppra/Keppra XR sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 15: Lamictal/Lamictal XR sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Lyrica sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 17: Onfi sales for epilepsy in the US ($m), 2016–25
Table 18: Vimpat sales for epilepsy across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 19: Neurologists surveyed for the epilepsy primary research study, 2016
Table 20: Neurologists surveyed for the epilepsy primary research study, 2016
Table 21: Diagnosis rates for epilepsy in the US, Japan, and five major EU markets, by country (%)
Table 22: Segmentation of epilepsy patients by seizure subtype in the US, Japan, and five major EU markets, by country (%)
Table 23: Segmentation of epilepsy patients by treatment response in the US, Japan, and five major EU markets, by country (%)
Table 24: Drug treatment rate for epilepsy in the US, Japan, and five major EU markets, by country (%)
Table 25: Leading therapies for epilepsy
Table 26: Leading drug treatments according to patient share across the US, Japan, and five major EU markets, by epilepsy subtype (%)
Table 27: Drug treatments for treatment-responsive POS in the US, Japan, and five major EU markets, by country (%)
Table 28: Drug treatments for treatment-refractory partial-onset seizures in the US, Japan, and five major EU markets, by country (%)
Table 29: Drug treatments for treatment-responsive generalized seizures in the US, Japan, and five major EU markets, by country (%)
Table 30: Drug treatments for treatment-refractory generalized seizures in the US, Japan, and five major EU markets, by country (%)
Table 31: Compliance rates of epilepsy patients in the US, Japan, and five major EU markets, by country, seizure type, and responsiveness to treatment (%)
Table 32: Sources used for the epidemiological analysis of epilepsy in the US, Japan, and five major EU markets, by country
Table 33: Diagnosed prevalent cases of active epilepsy in the US, Japan, and five major EU markets, by country, 2018–38
Table 34: Key marketed drugs for epilepsy
Table 35: Aptiom epilepsy indication approvals
Table 36: Aptiom drug profile
Table 37: Aptiom pivotal trial data in epilepsy
Table 38: Ongoing late-phase trials
Table 39: Banzel drug profile
Table 40: Banzel pivotal trial data in epilepsy
Table 41: Safety profile for Banzel in epilepsy
Table 42: Briviact drug profile
Table 43: Briviact pivotal trial data in epilepsy
Table 44: Fycompa epilepsy indication approvals
Table 45: Fycompa drug profile
Table 46: Fycompa pivotal trial data in epilepsy
Table 47: Ongoing late-phase trials
Table 48: Keppra/Keppra XR epilepsy indication approvals
Table 49: Keppra and Keppra XR drug profile
Table 50: Keppra pivotal trial data in epilepsy
Table 51: Safety profile for Keppra in epilepsy
Table 52: Keppra XR pivotal trial data in epilepsy
Table 53: Safety profile for Keppra XR in epilepsy
Table 54: Lamictal/Lamictal XR epilepsy indication approvals
Table 55: Lamictal and Lamictal XR drug profile
Table 56: Lamictal pivotal trial data in epilepsy
Table 57: Safety profile for Lamictal in epilepsy
Table 58: Lamictal XR pivotal trial data in epilepsy
Table 59: Safety profile for Lamictal XR in epilepsy
Table 60: Lyrica drug profile
Table 61: Lyrica pivotal trial data in epilepsy
Table 62: Safety profile for Lyrica in epilepsy
Table 63: Pfizer late-phase trial data in partial-onset epilepsy
Table 64: Lyrica ongoing late-phase trials for pediatric and adult epilepsy indications
Table 65: Onfi drug profile
Table 66: Onfi pivotal trial data in epilepsy
Table 67: Safety profile for Onfi in epilepsy
Table 68: Vimpat epilepsy indication approvals
Table 69: Vimpat drug profile
Table 70: Vimpat pivotal trial data in epilepsy
Table 71: Safety profile for Vimpat in epilepsy
Table 72: Vimpat late-phase trial data in epilepsy
Table 73: Vimpat ongoing late-phase clinical trials as monotherapy in epilepsy
Table 74: Pipeline products in development for epilepsy
Table 75: ZX008 Phase III trial in Dravet syndrome
Table 76: Epidiolex drug profile
Table 77: Epidiolex Phase II/III data in epilepsy
Table 78: Epidiolex physician-led expanded access program data
Table 79: Epidiolex Phase III trials in Dravet syndrome, tuberous sclerosis complex, and infantile spasms
Table 80: Ganaxolone drug profile
Table 81: Ganaxolone Phase II/III data in epilepsy
